🇮🇳IN
Sign In
GV

GVBL

BSE

Genomic Valley Biotech Ltd

₹48.01

-1.99(-3.98%)
FSI

Fundamental Strength Index

computed from the statements below↑ higher is better

Weights come from configuration, not from this page — each pillar links to the section below that explains it.

Income stmtHistory

Profitability

headline ratios

Growth

compounded, from filed annual results

Segment Results

₹ Cr

Working Capital & Efficiency

days · ROCE %

GVBL financial summary

For Mar 2026, Genomic Valley Biotech Ltd reported revenue of ₹0 crore, which fell 67.9% from the previous year. Net profit was ₹0 crore, which fell 91.7% year on year, on an operating margin of 15%. Earnings per share came in at ₹0.1. Over the 5 years from Mar 2021 to Mar 2026, revenue changed at a compound annual rate of 5.2%. The highest operating margin in that period was 52% in Mar 2025. Annual results are available for 12 financial years, from Mar 2015 to Mar 2026.

Revenue₹0 crore
Net profit₹0 crore
Operating margin15%
EPS₹0.1

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Disclaimer